It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction: The emergence of Carbapenem-resistant Enterobacteriaceae (CRE) is a major public health threat in India posing challenges in infection management. Our study aims to address the regional incidence of monomicrobial CRE in a metropolitan area of Kerala and characterize prescriptions in relation to clinical management.
Methodology: The multicentre, prospective observational study was conducted in secondary and tertiary care centres jointly following public-private partnership model in Ernakulam district of Kerala, India from October 2018 to October 2019.
Results: The overall incidence of monomicrobial CRE-positive cases from the study hospital network was found to be 0.855 per 1000 patient-days. Among the available data in the cohort, 77 % (312/405) were observed to attain clinical cure and in-hospital all-cause mortality was at 20% (83/410). The proportion of patients with clinical cure to treatment was found to be significantly higher than clinical failure among patients with urinary tract infections (p < 0.001, OR 2.88, 95% CI 1.73 – 4.79) and pneumonia (p < 0.001, OR 0.36, 95% CI 0.21 - 0.6) at 87% and 61% respectively in comparison to other infections. The prevalence of colistin resistance among the total number of patients recruited with isolated monomicrobial CRE was found to be at 3%.
Conclusions: Our prospective study on the regional epidemiology of monomicrobial CRE has revealed notable incidence and all-cause mortality. The antimicrobial regimens for clinical management detailed in the study and the assessment of focus of infection-based clinical cure status rates indicate the need of optimized antimicrobial therapy to improve treatment practices in CRE infections.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer






